Cargando…

Correlation between TSH Receptor Antibody Assays and Clinical Manifestations of Graves' Orbitopathy

PURPOSE: To investigate an association between the levels of serum thyroid-stimulating hormone (TSH)-receptor autoantibodies (TRAbs) and Graves' orbitopathy (GO) activity/severity scores, and compare the performance of three different TRAb assays in assessing the clinical manifestations of GO....

Descripción completa

Detalles Bibliográficos
Autores principales:	Jang, Sun Young, Shin, Dong Yeob, Lee, Eun Jig, Choi, Young Joon, Lee, Sang Yeul, Yoon, Jin Sook
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663223/ https://www.ncbi.nlm.nih.gov/pubmed/23709442 http://dx.doi.org/10.3349/ymj.2013.54.4.1033

Ejemplares similares

Graded Decompression of Orbital Fat and Wall in Patients with Graves' Orbitopathy
por: Lee, Kyou Ho, et al.
Publicado: (2014)

MicroRNA-27 inhibits adipogenic differentiation in orbital fibroblasts from patients with Graves’ orbitopathy
por: Jang, Sun Young, et al.
Publicado: (2019)

The Role of Adipsin, Complement Factor D, in the Pathogenesis of Graves’ Orbitopathy
por: Byeon, Hyeong Ju, et al.
Publicado: (2023)

Association of fibroblast growth factor 10 with the fibrotic and inflammatory pathogenesis of Graves’ orbitopathy
por: Jang, Sun Young, et al.
Publicado: (2021)

Therapeutic Potential of Targeting Periostin in the Treatment of Graves’ Orbitopathy
por: Jang, Sun Young, et al.
Publicado: (2022)

Quercetin Inhibits IL-1β-Induced Inflammation, Hyaluronan Production and Adipogenesis in Orbital Fibroblasts from Graves' Orbitopathy
por: Yoon, Jin Sook, et al.
Publicado: (2011)

Protein tyrosine phosphatase 1B as a therapeutic target for Graves’ orbitopathy in an in vitro model
por: Byeon, Hyeong Ju, et al.
Publicado: (2020)

Clinical utility of TSH receptor antibody levels in Graves’ orbitopathy: a comparison of two TSH receptor antibody immunoassays
por: Bluszcz, Gabriela A., et al.
Publicado: (2018)

Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves’ Orbitopathy in Orbital Fibroblasts
por: Lee, Ga Eun, et al.
Publicado: (2021)

Comparison Between Thyroid Stimulating Immunoglobulin and TSH-Receptor Antibodies in the Management of Graves’ Orbitopathy
por: Khamisi, Selwan, et al.
Publicado: (2023)

Therapeutic Effect of Guggulsterone in Primary Cultured Orbital Fibroblasts Obtained From Patients with Graves’ Orbitopathy
por: Kim, Bo Ram, et al.
Publicado: (2020)

TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy
por: Siderova, Mira, et al.
Publicado: (2018)

Potential Therapeutic Role of Bone Morphogenic Protein 7 (BMP7) in the Pathogenesis of Graves’ Orbitopathy
por: Kim, Bo Yi, et al.
Publicado: (2022)

Erratum to "Correlation between TSH Receptor Antibody Assays and Clinical Manifestations of Graves' Orbitopathy" by Jang SY, et al. (Yonsei Med J 2013;54:1033-9.)
Publicado: (2013)

Glycogen Synthase Kinase-3β Mediates Proinflammatory Cytokine Secretion and Adipogenesis in Orbital Fibroblasts from Patients with Graves’ Orbitopathy
por: Lee, Jihei Sara, et al.
Publicado: (2020)

Comparative assessment of Graves’ disease and main extrathyroidal manifestation, Graves’ ophthalmopathy, by non-targeted metabolite profiling of blood and orbital tissue
por: Ji, Dong Yoon, et al.
Publicado: (2018)

Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2020)

Update on the surgical management of Graves’ orbitopathy
por: Baeg, Joonyoung, et al.
Publicado: (2023)

Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy
por: Woo, Young Jae, et al.
Publicado: (2015)

Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015)

Correction to: Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2021)

Chemokine Expression during Adipogenesis and Inflammation in Orbital Fibroblasts from Patients with Graves' Orbitopathy
por: Lee, Chae Eun, et al.
Publicado: (2020)

Clinical Significance of Classification of Graves’ Disease According to the Characteristics of TSH Receptor Antibodies
por: Kim, Won Bae, et al.
Publicado: (2001)

Asymmetric Graves’ Orbitopathy
por: Panagiotou, Grigorios, et al.
Publicado: (2020)

Effects of Orbital Decompression on Lamina Cribrosa Depth in Patients with Graves' Orbitopathy
por: Seo, Yuri, et al.
Publicado: (2019)

Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves’ orbitopathy
por: Park, Jungyul, et al.
Publicado: (2023)

TSH receptor specific monoclonal autoantibody K1‐70(TM) targeting of the TSH receptor in subjects with Graves' disease and Graves' orbitopathy—Results from a phase I clinical trial
por: Furmaniak, Jadwiga, et al.
Publicado: (2022)

Risk Factors Associated with the Severity of Thyroid-Associated Orbitopathy in Korean Patients
por: Lee, Ji Hwan, et al.
Publicado: (2010)

Therapeutic effect of ibrutinib, a selective Bruton’s tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves’ orbitopathy
por: Park, Hyun Young, et al.
Publicado: (2022)

The Role of the Microbiota in Graves’ Disease and Graves’ Orbitopathy
por: Hou, Jueyu, et al.
Publicado: (2021)

Antioxidant Therapy in Graves’ Orbitopathy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Current Knowledge on Graves’ Orbitopathy
por: Gontarz-Nowak, Katarzyna, et al.
Publicado: (2020)

Orbital Signaling in Graves’ Orbitopathy
por: Draman, Mohd Shazli, et al.
Publicado: (2021)

Serum Selenium Levels in Patients with Graves Disease: Associations with Clinical Activity and Severity in a Retrospective Case-control Study
por: Kim, Tae Hwan, et al.
Publicado: (2022)

Stimulatory Thyrotropin Receptor Antibodies Are a Biomarker for Graves’ Orbitopathy
por: George, Augustine, et al.
Publicado: (2021)

Sex-specific risk factors associated with graves’ orbitopathy in Korean patients with newly diagnosed graves’ disease
por: Lee, Jooyoung, et al.
Publicado: (2023)

Graves’ disease and Graves’ orbitopathy following COVID-19
por: Lanzolla, G., et al.
Publicado: (2021)

Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Comparative performance of ELISA and dot blot assay for TSH‐receptor antibody detection in Graves’ disease
por: Zulkarnain, Zulkarnain, et al.
Publicado: (2022)

Graves′ orbitopathy: Management of difficult cases
por: Wiersinga, Wilmar M.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_cp5ieiloh0r6jouugjujrfgq6a